Compare SEB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEB | NAMS |
|---|---|---|
| Founded | 1918 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.6B |
| IPO Year | 1994 | N/A |
| Metric | SEB | NAMS |
|---|---|---|
| Price | $4,647.73 | $34.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $46.75 |
| AVG Volume (30 Days) | 5.7K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 467.71 | N/A |
| EPS | ★ 124.24 | N/A |
| Revenue | ★ $5,809,000,000.00 | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $37.53 | ★ N/A |
| Revenue Growth | ★ 7.99 | N/A |
| 52 Week Low | $2,446.37 | $16.79 |
| 52 Week High | $5,989.37 | $42.21 |
| Indicator | SEB | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 51.22 |
| Support Level | $4,258.94 | $34.05 |
| Resistance Level | $4,800.00 | $37.25 |
| Average True Range (ATR) | 262.03 | 2.29 |
| MACD | -76.04 | 0.36 |
| Stochastic Oscillator | 24.04 | 43.17 |
Seaboard Corp is a diversified group of companies that operate in agricultural, energy, and ocean transport businesses. The company is engaged in hog production, biofuel production, and pork processing in the United States; commodity trading and grain processing in Africa and South America; cargo shipping services in the U.S., Caribbean and Central and South America; sugar and alcohol production in Argentina; and electric power generation in the Dominican Republic. It also has an equity method investment in Butterball, LLC, a producer and processor of turkey products. The group's operating segments are; pork, commodity trading and milling, marine, liquid fuels, power, turkey, and others. It operates in 45 countries, with a concentration in the Caribbean, Central and South American region.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.